🇺🇸 FDA
Patent

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

granted A61KA61K2239/38A61K2239/48

Quick answer

US patent 12281329 (Compositions and methods for immune cell modulation in adoptive immunotherapies) held by Fate Therapeutics, Inc. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K2239/38, A61K2239/48, A61K2239/55, A61K2239/59